Anticoagulation for pediatric mechanical circulatory support

Pediatric Critical Care Medicine

Volumn 14, Issue 5 SUPPL, 2013, Pages

  Annich, Gail ^a   Adachi, Iki ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Activated clotting time; Extracorporeal membrane oxygenation; Heparin; Ventricular assist device

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; BLOOD CLOTTING FACTOR 10A ANTIBODY; DIPYRIDAMOLE; ENOXAPARIN; FRESH FROZEN PLASMA; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN ANTIBODY; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIFACTOR XA ASSAY; ARTICLE; ASSISTED CIRCULATION; BLEEDING; BLOOD CLOTTING TIME; CONSENSUS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZED CHILD; HUMAN; IMMUNOASSAY; LONG TERM CARE; LOW DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBOSIS; THROMBOSIS PREVENTION;

ADVANCED CARDIAC LIFE SUPPORT; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION TESTS; CHILD; DRUG MONITORING; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART-ASSIST DEVICES; HEMORRHAGE; HEPARIN; HUMANS; THROMBOSIS;

EID: 84880061497     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e318292dfa7     Document Type: Article

References (48)

1. Lequier LL, Annich GM, Massicotte P: Anticoagulation and bleeding during ECLS. In: ECMO: Extracorporeal Cardiopulmonary Support in Critical Care. Annich GM, MacLaren G (Eds). Ann Arbor, MI, ELSO, 2012, pp 157-170
2. Male C, Johnston M, Sparling C, et al: The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Clin Lab Med 1999; 19: 39-69 (Pubitemid 29217317)
3. Wan S, LeClerc JL, Vincent JL: Inflammatory response to cardiopulmonary bypass. Chest 1997; 112: 676-692
4. Peek GJ, Firmin RK: The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999; 45: 250-263 (Pubitemid 30116981)
5. Pratt CW, Church FC: Antithrombin: Structure and function. Semin Hematol 1991; 28: 3-9
6. Wu YI, Sheffield WP, Blajchman MA: Defining the heparin-binding domain of antithrombin. Blood Coagul Fibrinolysis 1994; 5: 83-95 (Pubitemid 24091326)
7. Danielsson A, Raub E, Lindahl U, et al: Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-15473 (Pubitemid 17208768)
8. Huang ZF, Wun TC, Broze GJ Jr: Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268:26950-26955 (Pubitemid 24006403)
9. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin. Chest 2004; 126:188S-203S
10. Olson J, Arkin C, Brandt J, et al: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782-798
11. Gruenwald C, de Souza V, Chan AK, et al: Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass. Perfusion 2000; 15: 203-209 (Pubitemid 30333164)
12. Guzzetta NA, Monitz HG, Fernandez JD, et al: Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg 2010; 111: 173-179
13. Raymond PD, Ray MJ, Callen SN, et al: Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by the activated clotting time. Perfusion 2003; 18: 277-281 (Pubitemid 37369282)
14. Martindale SJ, Shayevitz JR, D'Errico C: The activated coagulation time: Suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1996; 10: 458-463 (Pubitemid 26177753)
15. Urlesberger B, Zobel G, Zenz W, et al: Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996; 129: 264-268 (Pubitemid 27483799)
16. Nankervis CA, Preston TJ, Dysart KC, et al: Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53: 111-114 (Pubitemid 46145500)
17. Chan AK, Black L, Ing C, et al: Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 2008; 122: 135-136 (Pubitemid 351606295)
18. Kuhle S, Eulmesekian P, Kavanagh B, et al: Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92: 554-557 (Pubitemid 350144302)
19. Brill-Edwards P, Ginsberg JS, Johnston M, et al: Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-109 (Pubitemid 23286474)
20. Chan AK, Berry L, Monagle P, et al: Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults. Thromb Hemostat 2002; 87: 606-613 (Pubitemid 34302948)
21. Monagle P: Anticoagulation in the young. Heart 2004; 90: 808-812 (Pubitemid 38821078)
22. Alexander DC, Butt WW, Best JD, et al: Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. Thromb Res 2010; 125: 387-392
23. Miller BE, Bailey JM, Mancuso TJ, et al: Functional maturity of the coagulation system in children: An evaluation using thrombelastography. Anesth Analg 1997; 84: 745-748 (Pubitemid 27147694)
24. Yeh T Jr, Kavarana MN: Cardiopulmonary bypass and the coagulation system. Prog Pediatr Cardiol 2005; 21: 87-115 (Pubitemid 41773989)
25. Monagle P, Chalmers E, Chan A, et al: Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidenced-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133:887S-968S (Pubitemid 351892979)
26. Fleming GM, Gupta M, Cooley E, et al: Maintaining the standard: A quality assurance study for new equipment in the Michigan ECMO Program. ASAIO J 2007; 53: 556-560 (Pubitemid 47462249)
27. Schmidt B, Ofosu FA, Mitchell L, et al: Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-408 (Pubitemid 19099815)
28. Green TP, Isham-Schopf B, Irmiter RJ, et al: Inactivation of heparin during extracorporeal circulation in infants. Clin Pharmacol Ther 1990; 48: 148-154 (Pubitemid 20263243)
29. Shapiro A: Antithrombin deficiency in special clinical syndromes - Part I: Extracorporeal membrane oxygenation. Semin Hematol 1995; 32: 33-36 (Pubitemid 26030781)
30. Andrew M, Marzinotto V, Massicotte P, et al: Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res 1994; 35: 78-83 (Pubitemid 24004639)
31. Schmidt B, Andrew M: Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics 1995; 96(5 Part 1): 939-943
32. Arnold P, Jackson S, Wallis J, et al: Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 2001; 27: 1395-1400 (Pubitemid 32758938)
33. Pollock ME, Owings JT, Gosselin RC: ATIII replacement during infant extracorporeal support. Thromb Haemost 1995; 73:936
34. Thureen PJ, Loomis M, Manco-Johnson M, et al: Randomized trial of albumin versus plasma for correction of ATIII deficiency in neonatal ECMO. Second annual meeting of ELSO (Abst 50). 1990
35. Kelton JC: The pathophysiology of heparin-induced thrombocytopenia: Biological basis for treatment. Chest 2005; 127:9S-20S
36. Warkentin TE, Sheppard JA, Moore JC, et al: Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005; 146: 341-346 (Pubitemid 41712020)
37. Young G: New anticoagulants in children. Hematology 2008; 245-250
38. Bates SM, Weitz JI: The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12(Suppl F):27F-232
39. Young G, Yonekawa KE, Nakagawa PA, et al: Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban and bivalirudin. Blood Coagul Fibrinolysis 2007; 18: 547-553 (Pubitemid 47344302)
40. Beiderlinden M, Treschan T, Görlinger K, et al: Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007; 31: 461-465 (Pubitemid 46817376)
41. Scott LK, Grier LR, Conrad SA: Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatroban. Pediatr Crit Care Med 2006; 7: 473-475
42. Koster A, Weng U, Bottcher W, et al: Successful use of Bivalirudin as anticoagulant for ECMO in a patient with HIT. Ann Thorac Surg 2007; 83: 1865-1867 (Pubitemid 46616760)
43. Balasubramanian SK, Tiruvoipati R, Chatterjee S, et al: Extracorporeal membrane oxygenation with lepirudin anticoagulation for heparin induced thrombocytopenia. ASAIO J 2005; 5: 477-479 (Pubitemid 41076787)
44. Young G, Yonekawa KE, Nakagawa P, et al: Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion 2004; 19: 283-288 (Pubitemid 39359404)
45. Hetzer R, Alexi-Meskishvili V, Weng Y, et al: Mechanical cardiac support in the young with the BerlinHeart EXCOR pulsatile ventricular assist device: 15 years' experience. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2006; 99-108
46. Hetzer R, Potapov EV, Alexi-Meskishvili V, et al: Single-center experience with treatment of cardiogenic shock in children by pediatric ventricular assist devices. J Thorac Cardiovasc Surg 2011; 141:616-623, 623.e1
47. Almond CS, Buchholz H, Massicotte P, et al: Berlin Heart EXCOR Pediatric ventricular assist device investigational device exemption study: Study design and rationale. Am Heart J 2011; 162:425-435.e6
48. Fraser CD Jr, Jaquiss RD, Rosenthal DN, et al; Berlin Heart Study Investigators: Prospective trial of a pediatric ventricular assist device. N Engl J Med 2012; 367: 532-541